Rapport Therapeutics (RAPP) Income towards Parent Company (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Income towards Parent Company data on file, last reported at -$143.7 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 98.82% year-over-year to -$143.7 million in Q1 2026; TTM through Mar 2026 was -$474.1 million, a 96.13% increase from a year earlier, with the FY2025 full-year figure at -$225.3 million, down 187.74% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$143.7 million, up from -$147.6 million in the prior quarter.
• Over the last five years, Income towards Parent Company for RAPP reached as high as -$6.4 million in Q2 2023 and fell as low as -$12.2 billion in Q1 2025.
• Historically, Income towards Parent Company has averaged -$1.1 billion across 4 years, with a median of -$19.1 million in 2024.
• Across the five-year window, Income towards Parent Company tumbled 79809.42% in 2025 and soared 98.82% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$13.5 million in 2023, then sank by 47.79% to -$20.0 million in 2024, then plunged by 638.75% to -$147.6 million in 2025, then advanced by 2.65% to -$143.7 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$143.7 million in Q1 2026, -$147.6 million in Q4 2025, and -$139.3 million in Q3 2025.